Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Sep;5(18):376.
doi: 10.21037/atm.2017.06.48.

Beyond PD-L1 testing-emerging biomarkers for immunotherapy in non-small cell lung cancer

Khinh Ranh Voong  1 , Josephine Feliciano  2 , Daniel Becker  3 , Benjamin Levy  2   4
Affiliations
Review

Beyond PD-L1 testing-emerging biomarkers for immunotherapy in non-small cell lung cancer

Khinh Ranh Voong et al. Ann Transl Med. 2017 Sep.

Abstract

Recently, a firmer understanding of tumor immunology and tumor escape mechanisms has led to the development of immune checkpoint inhibitors, antibodies against programmed death-1 (PD-1) and its ligand (PD-L1). Nivolumab, pembrolizumab, and atezolizumab have dramatically altered the treatment paradigm in non-small cell lung cancer (NSCLC) and have each demonstrated improvements in outcomes and quality of life when compared to chemotherapy. Enrichment strategies to better select those patients more likely to respond have identified PD-L1 staining by immunohistochemistry (IHC) to be a predictive biomarker in both treatment naïve and refractory patients. Unfortunately, many challenges exist with this strategy and underscore the need for further exploration for more reliable biomarkers. Multiple tissue and plasma-based enrichment strategies have been identified in the hope of identifying patients more likely to benefit from checkpoint inhibitors. These include tumor mutational load; the "inflamed phenotype" including tumor infiltrating lymphocytes (TILS) and immunoscore; T-cell receptor clonality; gene signatures, and several plasma biomarkers. Several studies have revealed many of these biomarkers to be reliable predictors of response to immune checkpoint inhibitors across multiple tumor types. Given the small nature of these studies, additional prospective studies are warranted to formalize and validate each of these enrichment strategies.

Keywords: Biomarkers; immunotherapy; non-small cell lung cancer (NSCLC).

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: J Feliciano: Consulting from Takeda; research funding from Merck and Genentech. B Levy: Consulting from Astra-Zeneca, Celgene, Eli Lilly, Bristol Myers Squib, Genentech, and Takeda. The other authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Multiplex immunofluorescence (× 20) of a pulmonary adenocarcinoma shows tumor cells (white) surrounded by stromal and immune cells, including CD8+ T cells (yellow), regulatory T cells (green), and macrophages (magenta). PD-L1 (orange) is predominantly expressed on tumor cells while PD-1 (red) is seen on lymphocytes. Cell nuclei are shown in blue (DAPI). Image provided by Tricia R. Cottrell and Janis M. Taube.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Borghaei H, Brahmer J, Horn L, et al. P2.35: Nivolumab vs Docetaxel in Advanced NSCLC: CheckMate 017/057 2-Y Update and Exploratory Cytokine Profile Analysis: Track: Immunotherapy. J Thorac Oncol 2016;11:S237-S238. 10.1016/j.jtho.2016.08.106 - DOI - PubMed
    1. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med 2015;373:1627-39. 10.1056/NEJMoa1507643 - DOI - PMC - PubMed
    1. Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med 2015;373:123-35. 10.1056/NEJMoa1504627 - DOI - PMC - PubMed
    1. Reck M, Rodriguez-Abreu D, Robinson AG, et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med 2016;375:1823-33. 10.1056/NEJMoa1606774 - DOI - PubMed
    1. Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 2016;387:1540-50. 10.1016/S0140-6736(15)01281-7 - DOI - PubMed